RT Journal Article
SR Electronic
T1 Status of Anaplastic Lymphoma Kinase (ALK) in Malignant Mesothelioma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2589
OP 2592
VO 34
IS 5
A1 SERENA VARESANO
A1 CLAUDIO LEO
A1 SIMONA BOCCARDO
A1 SANDRA SALVI
A1 MAURO TRUINI
A1 PAOLA FERRO
A1 FRANCO FEDELI
A1 PIER ALDO CANESSA
A1 PAOLO DESSANTI
A1 MARIA PIA PISTILLO
A1 SILVIO RONCELLA
YR 2014
UL http://ar.iiarjournals.org/content/34/5/2589.abstract
AB Background: Malignant mesothelioma (MM) is a particularly aggressive type of primary tumor, associated with exposure to asbestos, and characterized by high mortality. To date, there is no curative therapy for MM. The receptor anaplastic lymphoma kinase (ALK) was found to be mutated in many cases of cancer and used as a target in biological therapies. We investigated whether this pharmacological treatment could also be applicable to MM. Materials and Methods: The state of ALK was analyzed by immunohistochemistry and fluorescent in situ hybridization in 63 MM tissue specimens. Results: None of the 63 MM samples showed overexpression or translocation of ALK. Conclusion: Our preliminary data exclude the utility of analysis of the ALK gene in MM and suggest that ALK inhibitor therapy is not applicable to MM.